The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients
- PMID: 27280467
- PMCID: PMC4900627
- DOI: 10.1371/journal.pone.0157189
The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients
Abstract
Introduction: Segregation of patients with cystic fibrosis (CF) was implemented to prevent chronic infection with epidemic Pseudomonas aeruginosa strains with presumed detrimental clinical effects, but its effectiveness has not been carefully evaluated.
Methods: The effect of strict segregation on the incidence of P. aeruginosa infection in CF patients was investigated through longitudinal protocolized follow-up of respiratory tract infection before and after segregation. In two nested cross-sectional studies in 2007 and 2011 the P. aeruginosa population structure was investigated and clinical parameters were determined in patients with and without infection with the Dutch epidemic P. aeruginosa clone (ST406).
Results: Of 784 included patients 315 and 382 were at risk for acquiring chronic P. aeruginosa infection before and after segregation. Acquisition rates were, respectively, 0.14 and 0.05 per 1,000 days at risk (HR: 0.66, 95% CI [0.2548-1.541]; p = 0.28). An exploratory subgroup analysis indicated lower acquisition after segregation in children < 15 years of age (HR: 0.43, 95% CI[0.21-0.95]; p = 0.04). P. aeruginosa population structure did not change after segregation and ST406 was not associated with lung function decline, death or lung transplantation.
Conclusions: Strict segregation was not associated with a statistically significant lower acquisition of chronic P. aeruginosa infection and ST406 was not associated with adverse clinical outcome. After segregation there were no new acquisitions of ST406. In an unplanned exploratory analysis chronic acquisition of P. aeruginosa was lower after implementation of segregation in patients under 15 years of age.
Conflict of interest statement
Figures


Similar articles
-
Pseudomonas aeruginosa genotype prevalence in Dutch cystic fibrosis patients and age dependency of colonization by various P. aeruginosa sequence types.J Clin Microbiol. 2009 Dec;47(12):4096-101. doi: 10.1128/JCM.01462-09. Epub 2009 Oct 14. J Clin Microbiol. 2009. PMID: 19828746 Free PMC article.
-
Clinical impact of a highly prevalent Pseudomonas aeruginosa clone in Dutch cystic fibrosis patients.Clin Microbiol Infect. 2011 Mar;17(3):382-5. doi: 10.1111/j.1469-0691.2010.03295.x. Epub 2010 Aug 30. Clin Microbiol Infect. 2011. PMID: 20807225
-
Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis.JAMA. 2010 Nov 17;304(19):2145-53. doi: 10.1001/jama.2010.1665. JAMA. 2010. PMID: 21081727
-
Eradication of early Pseudomonas infection in cystic fibrosis.Chron Respir Dis. 2009;6(2):99-107. doi: 10.1177/1479972309104661. Chron Respir Dis. 2009. PMID: 19411571 Review.
-
Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.Behring Inst Mitt. 1997 Feb;(98):249-55. Behring Inst Mitt. 1997. PMID: 9382747 Review.
Cited by
-
Current infection control practices used in Australian and New Zealand cystic fibrosis centers.BMC Pulm Med. 2020 Jan 17;20(1):16. doi: 10.1186/s12890-020-1052-y. BMC Pulm Med. 2020. PMID: 31952502 Free PMC article.
-
Ecology and Evolution of Chromosomal Gene Transfer between Environmental Microorganisms and Pathogens.Microbiol Spectr. 2018 Jan;6(1):10.1128/microbiolspec.mtbp-0006-2016. doi: 10.1128/microbiolspec.MTBP-0006-2016. Microbiol Spectr. 2018. PMID: 29350130 Free PMC article.
-
Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.Clin Microbiol Rev. 2018 Aug 29;31(4):e00019-18. doi: 10.1128/CMR.00019-18. Print 2018 Oct. Clin Microbiol Rev. 2018. PMID: 30158299 Free PMC article. Review.
-
Genomics of antibiotic-resistance prediction in Pseudomonas aeruginosa.Ann N Y Acad Sci. 2019 Jan;1435(1):5-17. doi: 10.1111/nyas.13358. Epub 2017 Jun 2. Ann N Y Acad Sci. 2019. PMID: 28574575 Free PMC article. Review.
-
Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01541-19. doi: 10.1128/AAC.01541-19. Print 2020 Jan 27. Antimicrob Agents Chemother. 2020. PMID: 31767727 Free PMC article.
References
-
- Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996. September 7;348(9028):639–42. - PubMed
-
- Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001. August 18;358(9281):557–8. - PubMed
-
- McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 2001. August 18;358(9281):558–60. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical